Combined chelation therapy with deferoxamine and deferiprone in β-thalassemia major: compliance and opinions of young thalassemic patients.
| Title | Combined chelation therapy with deferoxamine and deferiprone in β-thalassemia major: compliance and opinions of young thalassemic patients. |
| Publication Type | Journal Article |
| Year of Publication | 2014 |
| Authors | Hatzipantelis, E. S., Karasmanis K., Perifanis V., Vlachaki E., Tziomalos K., & Economou M. |
| Journal | Hemoglobin |
| Volume | 38 |
| Issue | 2 |
| Pagination | 111-4 |
| Date Published | 2014 |
| ISSN | 1532-432X |
| Keywords | Adolescent, Adult, beta-Thalassemia, Chelation Therapy, Chi-Square Distribution, Child, Deferoxamine, Drug Therapy, Combination, Health Knowledge, Attitudes, Practice, Humans, Iron Chelating Agents, Patient Compliance, Public Opinion, Pyridones, Surveys and Questionnaires, Young Adult |
| Abstract | Treatment of β-thalassemia major (β-TM) includes regular blood transfusions and iron chelation with subcutaneous injection of deferoxamine (DFO). During the last decade, a new chelation agent, deferiprone (L1), was introduced. The purpose of our study was to determine the level of awareness/education regarding chelation therapy, the degree of compliance to this therapy and their views of L1 in patients with β-TM. A relevant questionnaire was administered to 36 patients (12-26 years old) who were on combination chelation therapy with both DFO and L1. The majority of patients was well aware/educated about chelation therapy (76.6%), was compliant with this therapy (74.4%) and had a positive view towards oral chelation (86.0%). In conclusion, most patients with β-TM who were on combination chelation therapy with DFO and L1 were satisfied with this treatment and this results in high compliance rates. |
| DOI | 10.3109/03630269.2013.867407 |
| Alternate Journal | Hemoglobin |
| PubMed ID | 24351163 |
